• Explore /
  • Poster
  • / Trial of rucaparib in prostate indications 3 (TRITON3): An international, multicenter, randomized, open-label phase 3 study of rucaparib vs physician’s choice of therapy for patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD).

Trial of rucaparib in prostate indications 3 (TRITON3): An international, multicenter, randomized, open-label phase 3 study of rucaparib vs physician’s choice of therapy for patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD).

Abstract Poster

Authors

Charles Ryan

Charles J. Ryan

University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

Charles J. Ryan , Simon Paul Watkins , Darrin Despain , Chris Alan Karlovich , Andrew Simmons , Anthony A. Golsorkhi , Simon Chowdhury

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary (Prostate) Cancer

Track

Genitourinary Cancer—Prostate, Testicular, and Penile

Sub Track

Prostate Cancer - Advanced Disease

Clinical Trial Registration Number

NCT02975934

Citation

J Clin Oncol 35, 2017 (suppl; abstr TPS5087)

DOI

10.1200/JCO.2017.35.15_suppl.TPS5087

Abstract #

TPS5087

Poster Bd #

160b

Abstract Disclosures

Similar Posters

First Author: Charles J. Ryan

First Author: Wassim Abida

First Author: Benedito A. Carneiro

First Author: Johann S. De Bono